Neoadjuvant Targeted Therapy in Resectable Non-Small Cell Lung Cancer: Current and Future Perspectives

By sjmartinez • July 16, 2023

Lee JM, McNamee CJ, Toloza E, Negrao MV, Lin J, Shum E, Cummings AL, Kris MG, Sepesi B, Bara I, Kurtsikidze N, Schulze K, Ngiam C, Chaft JE. Neoadjuvant Targeted Therapy in Resectable Non-Small Cell Lung Cancer: Current and Future Perspectives. J Thorac Oncol. 2023 Jul 12:S1556-0864(23)00671-8. doi: 10.1016/j.jtho.2023.07.006. Epub ahead of print. PMID: 37451404.

Tags: Early-stage NSCLC, Hematology/Oncology, neoadjuvant treatment, NGS testing, Publications, Resectable NSCLC, targeted therapy

Response to Letter to the Editor: ‘NALIRIFOX versus nab-paclitaxel and gemcitabine in older patients with treatment-naive metastatic pancreatic cancer: a subgroup analysis of the pivotal NAPOLI 3 trial’

Macarulla T, Cid RP, Womack MS, Gracian AC, Zervoudakis A, Hatoum H, Chung V, Patel A, Paulson AS, Pant S, O'Reilly EM, Hubner RA, Van[...]

Autosomal allelic inactivation at loci with variable replication timing and dosage sensitivity

Heskett MB, Vouzas AE, Johnstone B, Freese KP, Yates PA, Copenhaver PF, Spellman PT, Gilbert DM, Thayer MJ. Autosomal allelic inactivation at loci with variable[...]

A phase Ib/II, open-label, multicenter, randomized umbrella study evaluating the combination of atezolizumab with sacituzumab govitecan in patients with locally advanced or metastatic urothelial carcinoma and previously treated with a platinum-based treatment regimen (MORPHEUS-Urothelial Carcinoma)

Shin SJ, Lee JL, Powles T, Martin-Liberal J, Morales-Barrera R, Drakaki A, Friedlander T, Joly F, Shah SA, Vuky J, Ianculescu I, Michielin F, Gan[...]